Cookies: We use cookies to improve your experience on our website. By using our website, you agree to our use of cookies.
    Category
  • Paper & Paper Products
  • Silver
  • Specialty Chemicals
  • Steel
  • Agricultural Inputs
  • Aluminum
  • Building Materials
  • Chemicals
  • Coking Coal
  • Copper
  • Gold
  • Lumber & Wood Production
  • Other Industrial Metals & Mining
  • Other Precious Metals & Mining
  • Electronic Gaming & Multimedia
  • Internet Content & Information
  • Publishing
  • Telecom Services
  • Advertising Agencies
  • Broadcasting
  • Entertainment
  • Leisure
  • Auto & Truck Dealerships
  • Luxury Goods
  • Personal Services
  • Recreational Vehicles
  • Residential Construction
  • Restaurants
  • Specialty Retail
  • Textile Manufacturing
  • Travel Services
  • Footwear & Accessories
  • Furnishings, Fixtures & Appliances
  • Packaging & Containers
  • Resorts & Casinos
  • Apparel Manufacturing
  • Apparel Retail
  • Auto Manufacturers
  • Auto Parts
  • Gambling
  • Home Improvement Retail
  • Internet Retail
  • Lodging
  • Packaged Foods
  • Beverages—Wineries & Distilleries
  • Tobacco
  • Beverages—Brewers
  • Beverages—Non-Alcoholic
  • Confectioners
  • Discount Stores
  • Farm Products
  • Food Distribution
  • Grocery Stores
  • Education & Training Services
  • Household & Personal Products
  • Oil & Gas Midstream
  • Thermal Coal
  • Uranium
  • Oil & Gas Refining & Marketing
  • Oil & Gas Integrated
  • Oil & Gas Equipment & Services
  • Oil & Gas Drilling
  • Oil & Gas E&P
  • Credit Services
  • Financial Conglomerates
  • Insurance Brokers
  • Insurance—Property & Casualty
  • Financial Data & Stock Exchanges
  • Insurance—Diversified
  • Insurance—Life
  • Insurance—Reinsurance
  • Insurance—Specialty
  • Mortgage Finance
  • Shell Companies
  • Banks—Diversified
  • Asset Management
  • Banks—Regional
  • Capital Markets
  • Waste Management
  • Aerospace & Defense
  • Airlines
  • Airports & Air Services
  • Building Products & Equipment
  • Business Equipment & Supplies
  • Conglomerates
  • Consulting Services
  • Electrical Equipment & Parts
  • Engineering & Construction
  • Farm & Heavy Construction Machinery
  • Industrial Distribution
  • Infrastructure Operations
  • Integrated Freight & Logistics
  • Marine Shipping
  • Metal Fabrication
  • Pollution & Treatment Controls
  • Railroads
  • Rental & Leasing Services
  • Security & Protection Services
  • Specialty Business Services
  • Specialty Industrial Machinery
  • Staffing & Employment Services
  • Tools & Accessories
  • Trucking
  • REIT—Mortgage
  • REIT—Office
  • REIT—Specialty
  • REIT—Retail
  • REIT—Residential
  • Real Estate Services
  • Real Estate—Development
  • Real Estate—Diversified
  • REIT—Diversified
  • REIT—Healthcare Facilities
  • REIT—Hotel & Motel
  • REIT—Industrial
  • Software - Services
  • Software - Infrastructure
  • Hardware, Equipment & Parts
  • Technology Distributors
  • Software - Application
  • Semiconductors
  • Software—Application
  • Software—Infrastructure
  • Solar
  • Internet Software/Services
  • Media & Entertainment
  • Application Software
  • Communication Equipment
  • Computer Hardware
  • Consumer Electronics
  • Electronic Components
  • Electronics & Computer Distribution
  • Information Technology Services
  • Scientific & Technical Instruments
  • Semiconductor Equipment & Materials
  • Utilities—Regulated Water
  • Utilities—Renewable
  • Utilities—Regulated Gas
  • Utilities—Regulated Electric
  • Utilities—Independent Power Producers
  • Utilities—Diversified
    • Regions
    Category
    Regions
    Reset Showing 1 – 10 of 1247
    Repro Med Systems Inc. SWOT, Financial and Strategic Analysis Report 2025

    KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Repro Med Systems Inc.. Repro Med Systems Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Repro Med Systems Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Repro Med Systems Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Repro Med Systems Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Repro Med Systems Inc. and all latest updates of the company are provided. The 2025 version of Repro Med Systems Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Replimune Group Inc. SWOT, Financial and Strategic Analysis Report 2025

    Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Replimune Group Inc.. Replimune Group Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Replimune Group Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Replimune Group Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Replimune Group Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Replimune Group Inc. and all latest updates of the company are provided. The 2025 version of Replimune Group Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Repligen Corporation SWOT, Financial and Strategic Analysis Report 2025

    Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Repligen Corporation. Repligen Corporation business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Repligen Corporation are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Repligen Corporation , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Repligen Corporation including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Repligen Corporation and all latest updates of the company are provided. The 2025 version of Repligen Corporation report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    RenovoRx Inc. SWOT, Financial and Strategic Analysis Report 2025

    RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of RenovoRx Inc.. RenovoRx Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of RenovoRx Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of RenovoRx Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of RenovoRx Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of RenovoRx Inc. and all latest updates of the company are provided. The 2025 version of RenovoRx Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    RenovaCare, Inc. SWOT, Financial and Strategic Analysis Report 2025

    RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Scottsdale, Arizona. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of RenovaCare, Inc.. RenovaCare, Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of RenovaCare, Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of RenovaCare, Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of RenovaCare, Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of RenovaCare, Inc. and all latest updates of the company are provided. The 2025 version of RenovaCare, Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Rennova Health, Inc. SWOT, Financial and Strategic Analysis Report 2025

    Rennova Health, Inc., together with its subsidiaries, provides health care services in the United States. As of December 31, 2021, it owns one operating hospital in Oneida, Tennessee; an acute care hospital and a physician's practice in Jamestown, Tennessee; and a rural clinic in Williamsburg, Kentucky. The company was founded in 2005 and is based in West Palm Beach, Florida. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Rennova Health, Inc.. Rennova Health, Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Rennova Health, Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Rennova Health, Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Rennova Health, Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Rennova Health, Inc. and all latest updates of the company are provided. The 2025 version of Rennova Health, Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    RENEURON GROUP PLC SWOT, Financial and Strategic Analysis Report 2025

    ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of RENEURON GROUP PLC. RENEURON GROUP PLC business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of RENEURON GROUP PLC are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of RENEURON GROUP PLC , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of RENEURON GROUP PLC including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of RENEURON GROUP PLC and all latest updates of the company are provided. The 2025 version of RENEURON GROUP PLC report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Reneo Pharmaceuticals Inc. SWOT, Financial and Strategic Analysis Report 2025

    Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Reneo Pharmaceuticals Inc.. Reneo Pharmaceuticals Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Reneo Pharmaceuticals Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Reneo Pharmaceuticals Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Reneo Pharmaceuticals Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Reneo Pharmaceuticals Inc. and all latest updates of the company are provided. The 2025 version of Reneo Pharmaceuticals Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Renalytix plc American Depositary Shares SWOT, Financial and Strategic Analysis Report 2025

    Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Renalytix plc American Depositary Shares. Renalytix plc American Depositary Shares business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Renalytix plc American Depositary Shares are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Renalytix plc American Depositary Shares , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Renalytix plc American Depositary Shares including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Renalytix plc American Depositary Shares and all latest updates of the company are provided. The 2025 version of Renalytix plc American Depositary Shares report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    REMSleep Holdings, Inc. SWOT, Financial and Strategic Analysis Report 2025

    REMSleep Holdings, Inc. focuses on the development and distribution of products to help people affected by sleep apnea worldwide. The company offers DeltaWave CPAP interface device to treat patients with sleep apnea. It serves home care dealers, private sleep labs, product end users, physicians, medical group, and hospitals, as well as medical associations. The company is headquartered in Tampa, Florida. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of REMSleep Holdings, Inc.. REMSleep Holdings, Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of REMSleep Holdings, Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of REMSleep Holdings, Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of REMSleep Holdings, Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of REMSleep Holdings, Inc. and all latest updates of the company are provided. The 2025 version of REMSleep Holdings, Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    UPTO 10% OFF
    $50
    $50
    UPTO 10% OFF
    Resources
    Company
    Sign up for Offers & Promotions
  • Company Logo
  • Company Logo
    • Copyright © 2025 SWOT Reports. All Rights Reserved.

    Designed and Developed by SWOT Reports